Apotex Becomes First to Gain Canadian Approval for Generic SEVMIA™ for Weight Management

Apotex Gains First Health Canada Approval for SEVMIA™

On June 30, 2026, Apotex Health Corp. proudly announced its milestone achievement as the first company to receive Health Canada’s approval for SEVMIA™, a generic version of semaglutide tailored for chronic weight management in adults. This revolutionary product represents a significant step forward in enhancing healthcare accessibility in Canada.

What is SEVMIA™?

SEVMIA™ is delivered through a multi-use pre-filled pen, allowing precise dosing of 1 mg, with each pen providing a total of 4 mg of medication. This product was specifically developed to meet the needs of patients struggling with obesity and weight management challenges.

In Canada, SEVMIA™ is indicated as an adjunct to lifestyle interventions such as a reduced calorie diet and increased physical activity. It's especially beneficial for adults with obesity (with a BMI of 30 kg/m² or higher) or those with overweight (a BMI of 27 kg/m² or higher) who suffer from weight-related health issues. Additionally, it may help reduce the risk of non-fatal myocardial infarction in adults with pre-existing cardiovascular conditions.

Apotex's Commitment to Healthcare

Apotex has been a leader in providing affordable medicines for over 50 years, and this approval underscores the company's dedication to improving healthcare access for Canadians. According to Martin Arès, President of Apotex Canada, “This approval reflects our ongoing efforts to expand access to high-quality treatment options in areas of significant and growing needs for patients.”

The launch of SEVMIA™ follows the recent approval of Apo-Semaglutide Injection™, further solidifying Apotex's portfolio in the realm of diabetes and weight management therapies. These advancements aim to provide greater support in addressing the rising rates of obesity and related conditions in Canada.

The Role of Orbicular Pharmaceutical Technologies

The success of SEVMIA™ was achieved in collaboration with Orbicular Pharmaceutical Technologies, which underscores the strength and capability within Canada’s pharmaceutical development landscape. Dr. M. S. Mohan, Managing Director at Orbicular, emphasized the importance of their partnership with Apotex, highlighting that the approval reflects both teams' scientific rigor in meeting Health Canada’s stringent regulations.

Addressing an Urgent Health Challenge

Obesity is recognized as a complex, chronic disease affecting millions of Canadians. With rising prevalence rates, there is an urgent need for effective treatments to enhance patient outcomes. The introduction of affordable pharmacological solutions like SEVMIA™ aims to alleviate some of the burdens placed on Canada’s healthcare system.

Looking Ahead

Apotex remains unwavering in its mission to develop trusted, high-quality generic medicines that ensure patient access while promoting resilience within the Canadian healthcare framework. Moving forward, healthcare professionals are encouraged to consult the complete Product Monograph for comprehensive details on usage, precautions, and patient monitoring associated with SEVMIA™.

Apotex continues to strive for excellence in pharmaceutical innovation, ensuring that all Canadians have access to high-quality, affordable healthcare options to improve their lives.

For more information about Apotex and its extensive product offerings, visit www.apotex.com.